Tissue-agnostic oncology offers new hope for patients with rare cancers — but only if we rethink how we test, treat and trial. In this op-ed, TRACER Director Taran Gujral, PhD, urges a shift toward biology-driven care, flexible trial design and broader access to molecular testing. When treatment is guided by how a tumor behaves instead of where it starts, rarity becomes a catalyst for innovation.
Read the full story here:
Gujral Lab, Fred Hutch
Deanna works directly with rare tumor samples donated by patients. Her work helps make the most of each precious sample by supporting tumor profiling, functional testing, and data generation that can help accelerate rare cancer research.
Uterine Mesenchymal Tumors Alliance (UMTA) connects patients, clinicians, pathologists and researchers to improve care for those affected by uterine mesenchymal tumors.